Hillstream BioPharma EBIT

As of the most recent data (June 2026), HILS shows a EBIT of $-54M. That compares with $-14M in the prior-year period — down 294.3% year over year. That is below the sector sector average of $-6.4M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, HILS's EBIT is now $-54M (was $-14M) — a 294.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Hillstream BioPharma is outperforming or lagging.

The its sector sector average EBIT is about $-6.4M. Hillstream BioPharma is at $-54M, which is lower that average. That is roughly 740.4% below the sector mean. Use the comparison chart on this page to see how HILS stacks up against individual peers as well.

Tracking HILS's ebit over time shows whether Hillstream BioPharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-54M That compares with $-14M in the prior-year period — down 294.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Hillstream BioPharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-54M) with ownership activity and broader fundamentals.